Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 14396-14410

  Zhang, Rui ^a   Zhang, Jingzhu ^a   Fang, Lingduo ^a   Li, Xi ^a   Zhao, Yue ^a   Shi, Wanying ^a   An, Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Cholinergic neuron; Neurobehavior; Sulforaphane

Indexed keywords

ACETYLCHOLINESTERASE; ALUMINUM; BROXURIDINE; CHOLINE ACETYLTRANSFERASE; GALACTOSE; SULFORAPHANE; ISOTHIOCYANIC ACID DERIVATIVE; SULFORAFAN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BODY WEIGHT; CELL PROLIFERATION; CHOLINERGIC NERVE CELL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE LESION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; SPECTROPHOTOMETRY; STEP-DOWN PASSIVE AVOIDANCE TEST; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; HIPPOCAMPAL CA1 REGION; PATHOLOGY;

ALUMINUM; ALZHEIMER DISEASE; ANIMALS; BODY WEIGHT; CA1 REGION, HIPPOCAMPAL; CHOLINERGIC NEURONS; FEMALE; GALACTOSE; IMMUNOHISTOCHEMISTRY; ISOTHIOCYANATES; MALE; MICE;

EID: 84930691812     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150814396     Document Type: Article

References (49)

1. Tanzi, R.E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 2005, 120, 545-555.
2. Wimo, A.; Winblad, B.; Aguero-Torres, H.; von Strauss, E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 2003, 17, 63-67.
3. Alagiakrishnan, K.; Gill, S.S.; Fagarasanu, A. Genetics and epigenetics of Alzheimer's disease. Postgrad. Med. J. 2012, 88, 522-529.
4. Blennow, K.; de Leon, M.J.; Zetterberg, H. Alzheimer's disease. Lancet 2006, 368, 387-403.
5. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
6. Francis, P.T.; Palmer A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J. Neurol. Neurosurg. 1999, 66, 137-147.
7. Gil-Bea, F.J.; García-Alloza, M.; Domínguez, J.; Marcos, B.; Ramírez, M.J. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neurosci. Lett. 2005, 375, 37-41.
8. Van Marum, R.J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. 2008, 22, 265-274.
9. Lleó, A; Greenberg, S.M.; Growdon, J.H. Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 2006, 57, 513-533.
10. Howes, M.J.; Perry, E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 2011, 28, 439-468.
11. Lee, C.; Park, G.H.; Lee, S.R.; Jang, J.H. Attenuation of β-amyloid-induced oxidative cell death by sulforaphane via activation of NF-E2-related factor 2. Oxid. Med. Cell. Longev. 2013, doi:10.1155/2013/313510.
12. Kim, H.V.; Kim, H.Y.; Ehrlich, H.Y.; Choi, S.Y.; Kim, D.J.; Kim, Y. Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 2013, 20, 7-12.
13. Xiao, F.; Li, X.G.; Zhang, X.Y.; Hou, J.D.; Lin, L.F.; Gao, Q.; Luo, H.M. Combined administration of D-galactose and aluminium induces Alzheimer-like lesions in brain. Neurosci. Bull. 2011, 27, 143-155.
14. Zhang, R.; Miao, Q.W.; Zhu, C.X.; Zhao, Y.; Liu, L.; Yang, J.; An, L. Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions. Am. J. Alzheimer's Dis. Other Demen. 2014, doi:10.1177/1533317514542645.
15. Musilli, M.; Nicolia, V.; Borrelli, S.; Scarpa, S.; Diana, G. Behavioral effects of Rho GTPase modulation in a model of Alzheimer's disease. Behav. Brain Res. 2013, 237, 223-229.
16. Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; Delon, M.R. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215, 1237-1239.
17. Fraser, D.D.; MacVicar, B.A. Cholinergic-dependent plateau potential in hippocampal CA1 pyramidal neurons. J. Neurosci. 1996, 16, 4113-4128.
18. Gu, H.; Long, D.; Song, C.; Li, X. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci. Lett. 2009, 453, 204-209.
19. Li, Q.; Chen, M.; Liu, H.; Yang, L.; Yang, G. Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment. Mol. Med. Rep. 2012, 6, 1450-1455.
20. Scali, C.; Giovannini, M.G.; Prosperi, C.; Bellucci, A.; Pepeu, G.; Casamenti, F. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 2003, 117, 909-919.
21. Zhou, L.; Zhu, S.; Wang L. The impact of Boschiakia Rossica extract on the Ach, ChAT and AChE of AD rats. Chin. Arch. Trad. Chin. Med. 2009, 27, 1874-1876. (In Chinese)
22. Giacobini, E. Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18, S1-S5.
23. DeKosky, S.T.; Ikonomovic, M.D.; Styren, S.D.; Beckett, L.; Wisniewski, S.; Bennett, D.A.; Cochran, E.J.; Kordower, J.H.; Mufson, E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51, 145-155.
24. Houghton, C.A.; Fassett, R.G.; Coombes, J.S. Sulforaphane: Translational research from laboratory bench to clinic. Nutr. Rev. 2013, 71, 709-726.
25. Alfieri, A.; Srivastava, S.; Siow, R.C.; Cash, D.; Modo, M.; Duchen, M.R.; Fraser, P.A.; Williams, S.C.; Mann, G.E. Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke. Free Radic. Biol. Med. 2013, 65, 1012-1022.
26. Dash, P.K.; Zhao, J.; Orsi, S.A.; Zhang, M.; Moore, A.N. Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci. Lett. 2009, 460, 103-107.
27. Morroni, F.; Tarozzi, A.; Sita, G.; Bolondi, C.; Zolezzi-Moraga, J.M.; Cantelli-Forti, G.; Hrelia, P. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology 2013, 36, 63-71.
28. Wu, X.; Zhao, J.; Yu, S.; Chen, Y.; Wu, J.; Zhao, Y. Sulforaphane protects primary cultures of cortical neurons against injury induced by oxygen-glucose deprivation/reoxygenation via antiapoptosis. Neurosci. Bull. 2012, 28, 509-516.
29. Wang, X.; de Rivero Vaccari, J.P.; Wang, H.; Diaz, P.; German, R.; Marcillo, A.E.; Keane, R.W. Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury. J. Neurotrauma 2012, 29, 936-945.
30. Goldman, S. Glia as neural progenitor cells. Trends Neurosci. 2003, 26, 590-596.
31. Alvarez-Buylla, A.; García-Verdugo, J.M.; Tramontin, A.D. A unified hypothesis on the lineage of neural stem cells. Nat. Rev. Neurosci. 2001, 2, 287-293.
32. Rockenstein, E.; Ubhi, K.; Doppler, E.; Novak, P.; Moessler, H.; Li, B.; Blanchard, J.; Grundke-Iqbal, I.; Iqbal, K.; Mante, M. et al. Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice. J. Alzheimer's Dis. 2011, 27, 743-752.
33. Lilja, A.M.; Röjdner, J.; Mustafiz, T.; Thomé, C.M.; Storelli, E.; Gonzalez, D.; Unger-Lithner, C.; Greig, N.H.; Nordberg, A.; Marutle, A. Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels. PLoS One 2013, 8, doi:10.1371/ journal.pone.0058752.
34. Choi, H.; Park, H.H.; Lee, K.Y.; Choi, N.Y.; Yu, H.J.; Lee, Y.J.; Park, J. Huh, Y.M.; Lee, S.H.; Koh, S.H. Coenzyme Q10 restores amyloid beta-inhibited proliferation of neural stem cells by activating the PI3K pathway. Stem Cells Dev. 2013, 22, 2112-2120.
35. Hu, Y.S.; Xu, P.; Pigino, G.; Brady, S.T.; Larson, J.; Lazarov, O. Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 mice. FASEB J. 2010, 24, 1667-1681.
36. Kamphuis, W.; Orre, M.; Kooijman, L.; Dahmen, M.; Hol, E.M. Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer's disease mouse model. Glia 2012, 60, 615-629.
37. Díaz-Moreno, M.; Hortigüela, R.; Gonçalves, A.; García-Carpio, I.; Manich, G.; García-Bermúdez, E.; Moreno-Estellés, M.; Eguiluz, C.; Vilaplana, J.; Pelegrí, C. et al. Aβ increases neural stem cell activity in senescence-accelerated SAMP8 mice. Neurobiol. Aging 2013, 34, 2623-2638.
38. Kanematsu, S.; Yoshizawa, K.; Uehara, N.; Miki, H.; Sasaki, T.; Kuro, M.; Lai, Y.C.; Kimura, A.; Yuri, T.; Tsubura, A. Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice. Oncol. Rep. 2011, 26, 603-608.
39. Li, S.H.; Fu, J.; Watkins, D.N.; Srivastava, R.K.; Shankar, S. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol. Cell. Biochem. 2013, 373, 217-227.
40. Chen, H.; Landen, C.N.; Li, Y. Alvarez, R.D.; Tollefsbol, T.O. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp. Cell Res. 2013, 319, 697-706.
41. Zanichelli, F.; Capasso, S.; Cipollaro, M.; Pagnotta, E.; Cartenì, M.; Casale, F.; Iori, R.; Galderisi, U. Dose-dependent effects of R-sulforaphane isothiocyanate on the biology of human mesenchymal stem cells, at dietary amounts, it promotes cell proliferation and reduces senescence and apoptosis, while at anti-cancer drug doses, it has a cytotoxic effect. Age 2012, 34, 281-293.
42. La Marca, M.; Beffy, P.; Della Croce, C.; Gervasi, P.G.; Iori, R.; Puccinelli, E.; Longo, V. Structural influence of isothiocyanates on expression of cytochrome P450, phase II enzymes, and activation ofNrf2 in primary rat hepatocytes. Food Chem. Toxicol. 2012, 50, 2822-2830.
43. Angeloni, C.; Leoncini, E.; Malaguti, M.; Angelini, S.; Hrelia, P.; Hrelia, S. Modulation of phase II enzymes by sulforaphane: Implications for its cardioprotective potential. J. Agric. Food Chem. 2009, 57, 5615-5622.
44. James, B.D.; Bennett, D.A.; Boyle, P.A.; Leurgans, S.; Schneider, J.A. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 2012, 307, 1798-1800.
45. Vom Berg, J.; Prokop, S.; Miller, K.R.; Obst, J.; Kälin, R.E.; Lopategui-Cabezas, I.; Wegner, A.; Mair, F.; Schipke, C.G.; Peters, O. et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 2012, 18, 1812-1819.
46. Paul, M.K.; Bisht, B.; Darmawan, D.O.; Chiou, R.; Ha, V.L.; Wallace, W.D.; Chon, A.T.; Hegab, A.E.; Grogan, T.; Elashoff, D.A. et al. Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent notch signaling. Cell Stem Cell 2014, doi:10.1016/j.stem.2014.05.009.
47. Hoetzenecker, W.; Echtenacher, B.; Guenova, E.; Hoetzenecker, K.; Woelbing, F.; Brück, J.; Teske, A.; Valtcheva, N.; Fuchs, K.; Kneilling, M. et al. ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat. Med. 2011, 18, 128-134.
48. Ukai, M.; Watanabe, Y.; Kameyama, T. Endomorphins 1 and 2, endogenous mu-opioid receptor agonists, impair passive avoidance learning in mice. Eur. J. Pharmacol. 2001, 421, 115-119.
49. Sakaguchi, M.; Koseki, M.; Wakamatsu, M.; Matsumura, E. Effects of systemic administration of beta-casomorphin-5 on learning and memory in mice. Eur. J. Pharmacol. 2006, 530, 81-87.